Hugo M. Horlings

TL;DR: The historical, premolecular data underpinning clinical understanding of AGCT was likely skewed by inclusion of misdiagnosed cases, and future management strategies should reflect the potential for surgical cure and long survival even after relapse.

TL;DR: The authors analyzed 681 triple-negative breast cancer (TNBC) patients for spatial immune cell contextures in relation to clinical outcomes and pathways of T cell evasion and showed that excluded, ignored and inflamed phenotype can be captured by a gene classifier that predicts prognosis of various cancers as well as anti-PD1 response of metastatic TNBC patients.

TL;DR: Evidence is provided that supports the idea that many published signatures track the same biological processes and that proliferation is one of them, and is a strong prognostic factor, with the potential to be converted into a predictive test.

TL;DR: It is suggested that future models for predicting breast cancer outcome should exploit both data types by employing a late OR or intermediate integration strategy based on nearest mean classifiers, which significantly outperforms all other classifiers.

TL;DR: Adjuvant!